CartiHeal Revenue and Competitors

Kfar Saba,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CartiHeal's estimated annual revenue is currently $3.4M per year.(i)
  • CartiHeal's estimated revenue per employee is $112,000

Employee Data

  • CartiHeal has 30 Employees.(i)
  • CartiHeal grew their employee count by 7% last year.

CartiHeal's People

NameTitleEmail/Phone
1
CEO & FounderReveal Email/Phone
2
R&D,Technical labReveal Email/Phone
3
Administarative CoordinatorReveal Email/Phone
4
Marketing SpecialistReveal Email/Phone
5
Research Development Laboratory TechnicianReveal Email/Phone
6
RNDReveal Email/Phone
7
Clinical Research Associate at CartiHealReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.1M1015%N/AN/A
#2
$1.6M19-71%N/AN/A
#3
$212.8M10635%$65MN/A
#4
$6.8M548%N/AN/A
#5
$12.9M922%$23.1MN/A
#6
$1M12N/AN/AN/A
#7
$106.5M599-17%$2.3MN/A
#8
$35.6M2316%N/AN/A
#9
$38.3M2495%N/AN/A
#10
$45M299-4%$102.6MN/A
Add Company

What Is CartiHeal?

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal's cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

keywords:N/A

N/A

Total Funding

30

Number of Employees

$3.4M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CartiHeal News

2022-03-30 - Bioventus Exercises Call Option to Acquire CartiHeal

“CartiHeal represents an important breakthrough for the treatment of osteoarthritis, and we are excited to bring this complementary product...

2022-03-30 - FDA approves CartiHeal's Implant for the Treatment of Cartilage and ...

CartiHeal, a privately-held medical device company headquartered in Israel and New Jersey, develops proprietary implants for the treatment of...

2022-03-30 - Bioventus exercises call option to acquire CartiHeal

“CartiHeal represents an important breakthrough for the treatment of osteoarthritis, and we are excited to bring this complementary product into...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M33-6%N/A
#2
$4.6M34-36%N/A
#3
$4.6M34-36%N/A
#4
$6.9M4132%N/A
#5
$10.8M410%N/A